BioSpace News Archive

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for the third quarter of fiscal 2022, ended June 30, 2022.

VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today reported its financial results for its first quarter of fiscal year 2023 ended June 30, 2022 and provided a corporate update.

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today reported recent business progress and second quarter 2022 financial results.

Athersys, Inc. announced its financial results for the three and six months ended June 30, 2022 and provided a business update.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today reported business and financial results for the third fiscal quarter of 2022 ended June 30, 2022.

Certara, Inc., a global leader in biosimulation, announced the sale by certain stockholders, including EQT Avatar Parent L.P., in an underwritten secondary offering of 7,000,000 shares of common stock of Certara pursuant to a registration statement filed by Certara with the U.S. Securities and Exchange Commission.

According to Vision Research Reports, the remote patient monitoring system market size is predicted to be worth around USD 5.7 billion by 2030, registering a CAGR of 20.1% during the forecast period 2022 to 2030.

According to Latest Report Study, the U.S. urgent care market is expected to surpass around USD 34.95 billion by 2030, poised to grow at a CAGR of 6.8% from 2022 to 2030.

The global generic pharmaceutical contract manufacturing market is expected to grow significantly during the forecast period.

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported financial results for the fiscal quarter ended June 30, 2022, and provided business updates.